IDH2 and central nervous system cancer: In the 12.5 version, the profile was classified as diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype (pHGG RTK1; 12.5 classifier score 0.90) We initiated radiochemotherapy in an accelerated hyperfractionated scheme with single doses of 1.6 Gy b.i.d. to a total dose of 59.2 Gy and concomitant temozolomide, followed by one cycle of temozolomide, five cycles of combined temozolomide/CCNU and TTF [6].